|
Name |
Trivirensol B
|
Molecular Formula | C45H60O15 | |
IUPAC Name* |
(5aS,6R,9S,9aS)-9-[[(5aS,6R,9S,9aS)-9-hydroxy-9-[[(E)-2-(hydroxymethyl)-3-[(4S,5R)-3-oxo-5-propan-2-yl-4,5,6,7-tetrahydro-1H-2-benzofuran-4-yl]prop-2-enoyl]oxymethyl]-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carbonyl]oxymethyl]-9-hydroxy-1-oxo-6-propan-2-yl-3,5a,6,7,8,9a-hexahydro-2-benzoxepine-4-carboxylic acid
|
|
SMILES |
CC(C)[C@H]1CCC2=C([C@@H]1/C=C(\CO)/C(=O)OC[C@@]3(CC[C@@H]([C@@H]4[C@@H]3C(=O)OCC(=C4)C(=O)OC[C@@]5(CC[C@@H]([C@@H]6[C@@H]5C(=O)OCC(=C6)C(=O)O)C(C)C)O)C(C)C)O)C(=O)OC2
|
|
InChI |
InChI=1S/C45H60O15/c1-22(2)29-8-7-25-17-56-41(51)35(25)32(29)13-26(16-46)39(49)59-20-44(54)12-10-31(24(5)6)34-15-28(19-58-43(53)37(34)44)40(50)60-21-45(55)11-9-30(23(3)4)33-14-27(38(47)48)18-57-42(52)36(33)45/h13-15,22-24,29-34,36-37,46,54-55H,7-12,16-21H2,1-6H3,(H,47,48)/b26-13+/t29-,30-,31-,32-,33-,34-,36-,37-,44-,45-/m1/s1
|
|
InChIKey |
YWJHSQZZKWLTCN-FEQABAOJSA-N
|
|
Synonyms |
CHEMBL4463460; Trivirensol B; BDBM50509324
|
|
CAS | NA | |
PubChem CID | 145721278 | |
ChEMBL ID | CHEMBL4463460 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 840.9 | ALogp: | 3.5 |
HBD: | 4 | HBA: | 15 |
Rotatable Bonds: | 14 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 230.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 60 | QED Weighted: | 0.122 |
Caco-2 Permeability: | -5.898 | MDCK Permeability: | 0.00001650 |
Pgp-inhibitor: | 0.018 | Pgp-substrate: | 0.606 |
Human Intestinal Absorption (HIA): | 0.319 | 20% Bioavailability (F20%): | 0.988 |
30% Bioavailability (F30%): | 0.996 |
Blood-Brain-Barrier Penetration (BBB): | 0.167 | Plasma Protein Binding (PPB): | 91.83% |
Volume Distribution (VD): | 0.448 | Fu: | 1.71% |
CYP1A2-inhibitor: | 0.011 | CYP1A2-substrate: | 0.091 |
CYP2C19-inhibitor: | 0.021 | CYP2C19-substrate: | 0.056 |
CYP2C9-inhibitor: | 0.283 | CYP2C9-substrate: | 0.015 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.042 |
CYP3A4-inhibitor: | 0.258 | CYP3A4-substrate: | 0.556 |
Clearance (CL): | 7.466 | Half-life (T1/2): | 0.03 |
hERG Blockers: | 0.172 | Human Hepatotoxicity (H-HT): | 0.627 |
Drug-inuced Liver Injury (DILI): | 0.946 | AMES Toxicity: | 0.026 |
Rat Oral Acute Toxicity: | 0.539 | Maximum Recommended Daily Dose: | 0.967 |
Skin Sensitization: | 0.267 | Carcinogencity: | 0.139 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.02 |
Respiratory Toxicity: | 0.828 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC004011 | 0.732 | D0FW2A | 0.220 | ||||
ENC004002 | 0.627 | D0ES1Q | 0.215 | ||||
ENC003999 | 0.526 | D0K7HU | 0.208 | ||||
ENC004063 | 0.367 | D0K3QS | 0.207 | ||||
ENC002578 | 0.305 | D03KPZ | 0.205 | ||||
ENC004919 | 0.303 | D06OMK | 0.204 | ||||
ENC005682 | 0.264 | D0Z4UN | 0.202 | ||||
ENC003589 | 0.238 | D03LJR | 0.201 | ||||
ENC005681 | 0.237 | D0T5XN | 0.198 | ||||
ENC004921 | 0.236 | D0X4RS | 0.197 |